Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.
Good Morning America, Phoenix and Seattle TV, Ophthalmology Times, OVR Magazine and more have covered A Race Against Blindness. The coverage, the research partners and the sponsors, with links.
Every dollar below has been paid out to research, made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.
$7.1M
total research funding, fully paid out · as of November 2026
2024
$3M awarded
October
$1M
December
$2M — announced Feb 2025
To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.
2025
$2.1M awarded
September
$1M
December
$1.1M — announced Jan 2026
To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance, and to close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.
2026
$2M awarded
June
$1M
November
$1M
Through two grants to the Foundation Fighting Blindness, to fund gene-agnostic research: in June, the Gund Vision Fund (formerly the RD Fund) and early-stage gene therapy delivery research with Dr. Thomas Mendel; in November, the Gund Vision Fund and regenerative research with Dr. Jin Woo Kim at KAIST. The Gund Foundation Challenge matched the $1,475,000 directed to the Fund dollar for dollar.
Is a race against blindness legit? Learn how real winners, public announcements, and transparent prize delivery prove our fundraisers are exactly what they claim to be.
Is a race against blindness legit? Learn how public nonprofit filings, financial transparency, and verifiable records support accountability and trust.
Is a race against blindness legit? Learn how independent platforms like the IRS, Candid, and Charity Navigator verify our nonprofit status and transparency.
Patient advocacy is now one of the most powerful drivers of progress in retinal gene therapy. Learn how nonprofit involvement, family voices, awareness, and fundraising are accelerating research for Bardet-Biedl Syndrome and inherited retinal diseases — and why this work matters now more than ever.
We recently attended the Gene Therapy for Ophthalmic Disorders Summit, where leading researchers and clinicians shared promising advances in retinal gene therapy. From new vision endpoints to breakthroughs in delivery methods and patient advocacy, the conference highlighted real progress toward treatments for BBS, RP, and other inherited retinal diseases. Here’s what we learned — and why it matters for families urgently waiting for hope.
The latest innovations in gene therapy — from optogenetics to engineered AAV capsids to AI-driven breakthroughs — are rapidly accelerating progress toward treatments for Bardet-Biedl Syndrome and other inherited retinal diseases. Here’s what these advances mean for families urgently awaiting hope.
This Gratitude Gallery shares real reviews and experiences from our community—honest messages of hope, faith, and resilience that remind us why this mission matters.
This special Gratitude Gallery shares real reviews and experiences from our community following a Christmas Eve message—expressions of hope, faith, and belief in miracles unfolding.
The FDA has approved the first-ever gene therapy for Wiskott-Aldrich syndrome, marking a major milestone for the rare disease community. While this treatment is not for vision loss, it represents important progress for gene therapy as a whole — and brings renewed hope for families awaiting treatments for inherited retinal diseases like BBS and retinitis pigmentosa.